利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

4364 条记录 (耗时 0.04 秒)

    NEW PROCESS FOR PRODUCING HUMIC ACID SALTS WITH FLUIDIZING SOLID PHASE REACTION
    2.
    发明申请
    NEW PROCESS FOR PRODUCING HUMIC ACID SALTS WITH FLUIDIZING SOLID PHASE REACTION 审中-公开

    公开(公告)号：US20200277238A9

    公开(公告)日：2020-09-03

    申请号：US15731032

    申请日：2017-04-10

    申请人： JAMES CHIN CHENG YANG

    发明人： JAMES CHIN CHENG YANG

    IPC分类号： C05F11/06 ,  B01J2/18 ,  B01F13/04 ,  C07D521/00 ,  B01J8/42 ,  B01J8/18

    摘要： The present invention utilizes a high-speed intensive mixer in fluidizing type solid phase neutralization reactor to blend solid state alkali hydroxide with any humic acid sources. The final product is a dry humic acid salt. The purpose of this innovative method is to eliminate a series of complicated unit operations commonly employed by the traditional process. These removed steps may include dissolving caustic soda, mixing in a paste like formation, extrusion, granulation, drying, and grinding, etc. The new invention contributes to a simplified flowsheet, resulting in sharply reduced equipment investment, the required plant space, and labor and energy costs. All these factors coupled with increased productivity will drastically lower the overall production cost. Also the reduction of dust pollution will greatly minimize the impact in environmental protection and safety issues.

    (1-azinone)-substituted pyridoindoles
    6.
    发明授权
    (1-azinone)-substituted pyridoindoles 有权

    公开(公告)号：US09650378B2

    公开(公告)日：2017-05-16

    申请号：US15045652

    申请日：2016-02-17

    申请人： Albany Molecular Research, Inc.

    发明人： Peter Guzzo ,  Matthew David Surman ,  Alan John Henderson ,  May Xiaowu Jiang ,  Mark Hadden ,  James Grabowski ,  Alexander Usyatinsky

    IPC分类号： C07D471/04 ,  C07D521/00 ,  C07D519/00

    CPC分类号： C07D471/04 ,  C07D519/00 ,  C07D521/00

    摘要： Substituted pyridoindoles for incorporation in pharmaceutical compositions employed in the treatment of various diseases correspond to formula (I) wherein R1 is H or optionally substituted alkyl; R2, R3, R4 are each independently selected from H, —O-alkyl, —S-alkyl, alkyl, halo, —CF3, and —CN; G is —CR12R13—NR5— or —NR5—CR12R13; R5 is H, optionally substituted alkyl, optionally substituted heterocycle, —C(═O)—R6, —C(═O)—O—R7, or —C(═O)—NR19R20; R6 and R7 are each optionally substituted alkyl or optionally substituted heterocycle; R8, R9, R10, R11, R12, R13, R19 and R20 are each independently selected from H or optionally substituted alkyl; R14 and R15 are each independently H or halogen; L is —CH2—O—, —CH2CH2—, —CH═CH— or a bond; and B is aryl or heteroaryl or cycloalkyl; with the proviso that, when L is a direct bond, B cannot be unsubstituted heteroaryl or heteroaryl monosubstituted with fluorine.

    Compounds derived from artesunate, preparation process, pharmaceutical composition and use of the respective medicine
    7.
    发明授权
    Compounds derived from artesunate, preparation process, pharmaceutical composition and use of the respective medicine 有权
    衍生自青蒿琥酯的化合物，制备方法，药物组合物和各药物的使用

    公开(公告)号：US08802701B2

    公开(公告)日：2014-08-12

    申请号：US13686600

    申请日：2012-11-27

    申请人： Fundação Oswaldo Cruz

    发明人： Nubia Boechat ,  Marcus Vinicius Nora de Souza ,  Alessandra Leda Valverde ,  Antoniana Ursine Krettli

    IPC分类号： C07D215/14 ,  A61K31/35 ,  A61K31/47 ,  A61K31/55 ,  A61K45/00 ,  A61P33/06 ,  C07D215/46 ,  C07D493/18 ,  C07D493/22 ,  C07D521/00

    CPC分类号： C07D215/14 ,  A61K31/35 ,  C07D215/46 ,  C07D493/18 ,  C07D493/22 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  Y02A50/423 ,  Y02A50/486 ,  Y02A50/491

    摘要： The present invention refers to new compounds represented by the general formula (I) where X is represented by the general formula (II) and Y is represented by the general formula (III). The relation X to Y may vary from 1:1 to 1:7. The radicals R1, R2, R3, R4, R5, and R6 in formula (II) are represented by: R1=H, CF3, CH3, OCH3, NH2, halogen; R2=H, CH3, NH2, halogen, NH—CHCH3(CH2)3N(C2H5)(CH2CH2OH), CH(OH)-2(C5H11N), NH—R7—N—(C2H5)2; R3=H, m-OC6H4CF3, NH2; R4=H, CH3, OCH3, NH2, halogen; R5=H, CH3, CF3, NH2, halogen; R6=H, CF3, CH3, NH2, halogen, NH—R8—N—(C2H5)2, NHCH(CH3)(CH2)3NH2; R7=(CH2)2, (CH2)3, CHCH3CH2, (CH2)4, (CH2)5, CHCH3(CH2)3, (CH2)6, (CH2)8, (CH2)10, (CH2)12; R8=CHCH3(CH2)3, CHCH3(CH2)CHCH3, (CH2)2, (CH2)3, (CH2)6, (CH2)3O(CH2)3. This invention also refers to a process of preparation of these compounds (formula I), and antiparasitic pharmaceutical compositions thereof.

    摘要翻译： 本发明涉及由通式（I）表示的新化合物，其中X由通式（II）表示，Y由通式（III）表示。 关系X至Y可以从1:1到1:7变化。 式（II）中的基团R 1，R 2，R 3，R 4，R 5和R 6表示为：R 1 = H，CF 3，CH 3，OCH 3，NH 2，卤素; R2 = H，CH3，NH2，卤素，NH-CHCH3（CH2）3N（C2H5）（CH2CH2OH），CH（OH）-2（C5H11N），NH-R7-N-（C2H5） R3 = H，m-OC6H4CF3，NH2; R4 = H，CH3，OCH3，NH2，卤素; R5 = H，CH3，CF3，NH2，卤素; R6 = H，CF3，CH3，NH2，卤素，NH-R8-N-（C2H5）2，NHCH（CH3）（CH2）3NH2; R7 =（CH2）2，（CH2）3，CHCH3CH2，（CH2）4，（CH2）5，CHCH3（CH2）3，（CH2）6，（CH2）8，（CH2）10，（CH2） R8 = CHCH3（CH2）3，CHCH3（CH2）CHCH3，（CH2）2，（CH2）3，（CH2）6，（CH2）3O（CH2） 本发明还涉及制备这些化合物（式I）的方法及其抗寄生虫药物组合物。

    Constrained spirocyclic compounds as CGRP receptor antagonists
    8.
    发明授权
    Constrained spirocyclic compounds as CGRP receptor antagonists 有权
    约束螺环化合物作为CGRP受体拮抗剂

    公开(公告)号：US07951795B2

    公开(公告)日：2011-05-31

    申请号：US12517674

    申请日：2007-12-05

    申请人： Ian M. Bell ,  Harold G. Selnick

    发明人： Ian M. Bell ,  Harold G. Selnick

    IPC分类号： C07D521/00 ,  A61K31/5517 ,  A61P25/06

    CPC分类号： C07D487/04

    摘要： Compounds of formula I: (wherein variables A1, A2, A3, G1, G2, G3, J, m, n, p, R1, R2, R3, R4 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

    摘要翻译： 式I化合物（其中变量A1，A2，A3，G1，G2，G3，J，m，n，p，R1，R2，R3，R4和Y如本文所述），其是CGRP受体的拮抗剂， 可用于治疗或预防涉及CGRP的疾病，如偏头痛。 本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在预防或治疗涉及CGRP的疾病中的用途。